Who is sponsoring NCT02197182?

NCT02197182 is sponsored by CDA Research Group, Inc..

What condition does NCT02197182 study?

NCT02197182 studies Bacterial Vaginosis (BV).

What drugs are being tested in NCT02197182?

Interventions: LUXSOL copper containing cream, Metronidazole gel.

What is the status of NCT02197182?

NCT02197182 is currently TERMINATED.

Last reviewed 2018-04-04 · How we verify

An Open-Label, Randomized Study to Determine the Safety and Efficacy of LUXSOL(TM) Cream for the Treatment of Bacterial Vaginosis: A Proof of Concept Study

NCT02197182 EARLY_PHASE1 TERMINATED

LUXSOL Cream may be useful for the treatment of bacterial Vaginosis. In this study, LUXSOL Cream is compared to a control arm group using metronidazole cream. LUXSOL is administered intravaginally for 10 days, each evening before bedtime to treat bacterial Vaginosis..

Details

Lead sponsor	CDA Research Group, Inc.
Phase	EARLY_PHASE1
Status	TERMINATED
Enrolment	50
Start date	2014-06
Completion	2015-03

Conditions

Bacterial Vaginosis (BV)

Interventions

LUXSOL copper containing cream
Metronidazole gel

Primary outcomes

Presence or absence of bacterial vaginosis at the end of the study — 30 days
Patients will be assessed at day 30 for the presence or absence of bacterial Vaginosis (BV). Absence of BV will be considered a cure.

Countries

United States